Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INO-4201 booster in VSV-ZEBOV vaccinated healthy volunteers
NCT04906629Phase 1Completed
- Sponsor
- Université de Genève
- Start
- Sep 2021
- Primary completion
- Jan 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of INO-4201 in Ebola virus disease (EVD), sponsored by Université de Genève. Primary endpoints: Incidence of adverse events at 14 days and Geometric mean titers of EBOV-GP-binding IgG antibodies at 4 weeks. Started Sep 2021; status: completed.
02
Drugs
INO-4201
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT04906629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906629.